Stay updated on Azacitidine±Nivolumab/Midostaurin in Older AML Clinical Trial
Sign up to get notified when there's something new on the Azacitidine±Nivolumab/Midostaurin in Older AML Clinical Trial page.

Latest updates to the Azacitidine±Nivolumab/Midostaurin in Older AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed study objectives and inclusion/exclusion criteria for a clinical trial, while adding new drug information and a revision number.SummaryDifference11%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 19, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a more recent last update date of March 25, 2025, replacing the previous version (v2.14.2) and last update date of March 19, 2025.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to reflect the latest study results comparing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in treatment-naïve adults with HIV-1 and hepatitis B virus (HBV) co-infection, including new data on participant outcomes and study phases.SummaryDifference26%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Azacitidine±Nivolumab/Midostaurin in Older AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine±Nivolumab/Midostaurin in Older AML Clinical Trial page.